Drug intelligence / Profile preview

WJ22096

Development stage: Phase 2
Lead developer: Nanjing Jingao Biomedical Technology
Modality: Small Molecules
Administration: Oral

Overview

**WJ22096** is an investigational small molecule inhibitor of focal adhesion kinase (FAK) developed by Nanjing Jingao Biomedical Technology Co., Ltd. for the treatment of advanced solid tumors. Administered orally as tablets once daily after meals, it is being evaluated in a Phase I/II trial (NCT07253116) assessing safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors refractory to standard therapies, including non-small cell lung cancer (NSCLC, prioritizing KRAS G12C mutations), colorectal cancer (CRC), and pancreatic cancer. The trial includes dose escalation, expansion, and efficacy cohorts to determine the recommended Phase 2 dose (RP2D).

Targets

FAK (Focal adhesion kinase)

Beyond the preview

Go deeper on WJ22096.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WJ22096.

Explore the full profile